Olga G. Skibina

99 Commercial Rd
Melbourne, VIC 3004, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 76 publications

Multiple sclerosis outcomes after cancer diagnosis in people with recorded chemotherapy exposure: A real-world MSBase study.

Multiple sclerosis outcomes after cancer diagnosis in people with recorded chemotherapy exposure: A real-world MSBase study.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: August 03, 2026

Association between pregnancy timing and disability outcomes in women with mild relapse-onset multiple sclerosis.

Association between pregnancy timing and disability outcomes in women with mild relapse-onset multiple sclerosis.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: July 29, 2026

Impact of multiple sclerosis disease-modifying therapies on chronic lesion tissue expansion.

Impact of multiple sclerosis disease-modifying therapies on chronic lesion tissue expansion.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: July 01, 2026

Modern diagnosis and treatment of multiple sclerosis: advances, challenges, and future directions.

Modern diagnosis and treatment of multiple sclerosis: advances, challenges, and future directions.

Journal: Autoimmunity reviews

Published: May 11, 2026

Comparative effectiveness of ofatumumab and ocrelizumab in relapsing multiple sclerosis: a target trial emulation using multinational registry data.

Comparative effectiveness of ofatumumab and ocrelizumab in relapsing multiple sclerosis: a target trial emulation using multinational registry data.

Journal: Journal of neurology, neurosurgery, and psychiatry

Published: April 28, 2026

Corrigendum to "Real-world effectiveness of ocrelizumab in relapsing multiple sclerosis: An MSBase registry sub-study" [Multiple Sclerosis and Related Disorders Vol 106; Feb 2026; Article Number 106885].

Corrigendum to "Real-world effectiveness of ocrelizumab in relapsing multiple sclerosis: An MSBase registry sub-study" [Multiple Sclerosis and Related Disorders Vol 106; Feb 2026; Article Number 106885].

Journal: Multiple sclerosis and related disorders

Published: April 10, 2026

Treatment escalation after clinically silent MRI lesions in relapsing-remitting multiple sclerosis.

Treatment escalation after clinically silent MRI lesions in relapsing-remitting multiple sclerosis.

Journal: Brain : a journal of neurology

Published: March 12, 2026

Circulatory immune cell counts and clinical outcomes in multiple sclerosis relapse versus remission.

Circulatory immune cell counts and clinical outcomes in multiple sclerosis relapse versus remission.

Journal: Journal of the neurological sciences

Published: February 05, 2026

Comparative effectiveness of ocrelizumab in subgroups of patients with multiple sclerosis: a multi-registry observational cohort study.

Comparative effectiveness of ocrelizumab in subgroups of patients with multiple sclerosis: a multi-registry observational cohort study.

Journal: Journal of neurology, neurosurgery, and psychiatry

Published: January 13, 2026

Managing reactivation of multiple sclerosis during treatment with natalizumab.

Managing reactivation of multiple sclerosis during treatment with natalizumab.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: December 20, 2025

Effect of late-onset on multiple sclerosis phenotype and outcome: evidence from a multi-national registry.

Effect of late-onset on multiple sclerosis phenotype and outcome: evidence from a multi-national registry.

Journal: Journal of neurology

Published: November 01, 2025

Menopause Impact on Multiple Sclerosis Disability Progression.

Menopause Impact on Multiple Sclerosis Disability Progression.

Journal: JAMA neurology

Published: September 29, 2025

Showing 1-12 of 76

Last Updated: 09/26/2026